MedTrace Logo

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2014-01-07

No results posted yet for this study

Summary

The investigators are conducting a research study to understand how cells responsible for fighting infection (immune cells) are affected by hormonal contraceptive use. The investigators hypothesize that progestin-containing hormonal contraceptives (i.e., Depo-Provera) inhibit host response to infection. To test this hypothesis, the investigators will collect blood and genital tract samples from women before and after their initiation of a hormonal contraceptive (either birth control pills, Depo-Provera, or Mirena).

Conditions

  • Initiation of Oral Contraception (OC)
  • Initiation of Depo-Provera (DMPA)
  • Initiation of Mirena (LNG-IUD)

Interventions

DRUG

Mirena

DRUG

Oral contraception

DRUG

Depo-Provera

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Thomas Cherpes, DVM, MD

    lead OTHER

Principal Investigators

  • Thomas L. Cherpes, MD · assistant professor

Eligibility

Min Age
15 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-04-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01750476 on ClinicalTrials.gov